More than 40 years of innovative diagnostics
Recently, DRG developed the world’s first nonradioactive immunoassays for the determination of active Renin and PLGF as well as a complete panel of sensitive assays for the quantitative determination of saliva steroids. In the last five years, we have developed our own tumor marker panel and a broad range of ELISAs in the field of infectious diseases, including the world’s first assay for the qualitative detection of human Fasciola IgG.
The DRG serum steroid ELISAS like 17-OH Progesterone, DHEA, Testosterone and other bestsellers, have held a leading position in the field of gynecologic endocrinology worldwide for many years.
Our newest development is an ELISA for the determination of 25-OH Vitamin D Total, a sensitive assay, which correlates perfectly to established RIAs.
In addition to our in-house developed and manufactured assays, we offer a wide range of innovative assays, both ELISAs and RIAs, in OEM format, in the fields of autoimmunity, immunology, bone and mineral and many others.
At the end of 2008, DRG began development of a closed system, our DRG:HYBRiD-XL, a fully automated analyzer for the simultaneous determination of immunoassays, as well as clinical chemistry.
- Drug monitoring
- Fertility & Pregnancy
- Pituitary / Adrenal function
- Cardiovascular disease
- Bone and mineral metabolism
- Leukotrienes and Prostaglandins
- Thyroid function
- Saliva Diagnostics
- Vitamin status
- Growth factors